KASINGER JAMES R. 4

What Happened

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics (CRSP), had multiple equity-related transactions around March 20–23, 2026. He sold 3,182 common shares in an open‑market sale on 2026-03-23 at $46.78/share for total proceeds of $148,854. On 2026-03-20 he received new awards (an option covering 38,499 shares and an RSU award for 25,000 shares) and had 6,250 units convert/vest (derivative conversion tied to a prior RSU grant).
• The sale reported was a sell-to-cover/tax‑related disposition associated with vesting shares (not a discretionary large sell). Some acquired shares remain subject to a lock‑up with underwriters.

Key Details

• Transactions/dates:
  • 2026-03-20: Conversion/exercise of derivative for 6,250 shares (derivative vest/convert).
  • 2026-03-20: Grant/award of 38,499 shares (option) and 25,000 RSUs (new grant).
  • 2026-03-23: Open‑market sale of 3,182 shares at $46.78 for $148,854 (disposed).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes:
  • F1: Some shares remain subject to a lock‑up with underwriters of the issuer’s 2031 convertible note offering.
  • F2: Each RSU is a contingent right to one common share.
  • F3: The reported sale amount represents shares sold to satisfy tax withholding for vested RSUs per the company’s RSU Settlement Policy (a mandated sell‑to‑cover, not a discretionary trade).
  • F4/F5/F6: Vesting schedules—the 38,499‑share option vests monthly over 48 months starting 4/20/2026; the 25,000 RSU grant vests in quarterly annual installments from 3/20/2027–3/20/2030; a 25,000 RSU grant from 2024 had one quarter (6,250 shares) vesting on 3/20/2026.
• Filing timeliness: The Form 4 was filed 2026-03-24 for transactions dated 2026-03-20 and 2026-03-23; this filing date is within the typical two business‑day reporting window and appears timely.

Context

• Derivative/RSU explanation: The 6,250‑share “M” entries reflect vested RSUs converting into common shares. The sale reported (3,182 shares) was a sell‑to‑cover to satisfy tax withholding obligations on vesting—common practice and not necessarily a signal of discretionary insider selling.
• Awards vs. sales: The filing shows both newly granted compensation (options and RSUs) and a routine tax‑related sale. Purchases (which can signal direct bullish insider conviction) are not present here; the sale was mandated by company policy.